Literature DB >> 25646791

Prevalence of kidney stones and vertebral fractures in primary hyperparathyroidism using imaging technology.

Cristiana Cipriani1, Federica Biamonte, Aline G Costa, Chiyuan Zhang, Piergianni Biondi, Daniele Diacinti, Jessica Pepe, Sara Piemonte, Alfredo Scillitani, Salvatore Minisola, John P Bilezikian.   

Abstract

CONTEXT: The fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism (PHPT) has recently suggested that skeletal and renal imaging be routinely conducted. So far, no study has systematically assessed this issue.
OBJECTIVE: The objective was to evaluate the prevalence of kidney stones (KS) and vertebral fractures (VFs) in a cohort of patients with PHPT utilizing noninvasive imaging technology.
DESIGN: This was a prospective study evaluating patients consecutively diagnosed with PHPT in a single center over a 5-year period (2009-2013).
SETTING: The setting was a referral center. PATIENTS: There were a total of 140 patients with PHPT (127 women [18 premenopausal and 109 postmenopausal] and 13 men; mean age, 63.2 ± 11 y). MAIN OUTCOMES MEASURES: Main outcome measures were the prevalence of KS by abdominal ultrasound, osteoporosis by dual-energy x-ray absorptiometry (DXA) (lumbar spine, femoral neck, total hip, and distal 1/3 radius), and VFs by vertebral spine x-ray, with attention to those categorized as symptomatic or asymptomatic.
RESULTS: Fifty-five percent of all subjects had KS by ultrasound, 62.9% had osteoporosis by T-score at any site, and 35.1% had VFs by x-ray. There was no difference in the incidence of VFs and densitometric osteoporosis between symptomatic and asymptomatic patients (VFs, 34.4 vs 34.7%; osteoporosis by DXA, 59.4 vs 65.8%), whereas more KS were detected in symptomatic (78%) than asymptomatic (35.5%). Twenty-two percent of patients classified as asymptomatic at baseline without osteoporosis by DXA were found to have KS and/or VFs.
CONCLUSIONS: Nephrolithiasis and VFs are common in asymptomatic subjects with PHPT. The results provide evidence in support of recent recommendations that a more proactive approach be taken to detect silent bone and stone disease in asymptomatic PHPT.

Entities:  

Mesh:

Year:  2015        PMID: 25646791      PMCID: PMC4399306          DOI: 10.1210/jc.2014-3708

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  32 in total

1.  Definition of a population-specific DXA reference standard in Italian women: the Densitometric Italian Normative Study (DINS).

Authors:  M Pedrazzoni; G Girasole; F Bertoldo; G Bianchi; C Cepollaro; A Del Puente; S Giannini; S Gonnelli; D Maggio; C Marcocci; S Minisola; E Palummeri; M Rossini; L Sartori; L Sinigaglia
Journal:  Osteoporos Int       Date:  2003-10-03       Impact factor: 4.507

2.  Renal stones and calcifications in patients with primary hyperparathyroidism: associations with biochemical variables.

Authors:  Jakob Starup-Linde; Elin Waldhauer; Lars Rolighed; Leif Mosekilde; Peter Vestergaard
Journal:  Eur J Endocrinol       Date:  2012-04-03       Impact factor: 6.664

3.  Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism.

Authors:  P Vestergaard; C L Mollerup; V G Frøkjaer; P Christiansen; M Blichert-Toft; L Mosekilde
Journal:  BMJ       Date:  2000-09-09

4.  Risk of renal stone events in primary hyperparathyroidism before and after parathyroid surgery: controlled retrospective follow up study.

Authors:  Charlotte L Mollerup; Peter Vestergaard; Vibe Gedsø Frøkjaer; Leif Mosekilde; Peer Christiansen; Mogens Blichert-Toft
Journal:  BMJ       Date:  2002-10-12

5.  Fractures in patients with primary hyperparathyroidism: nationwide follow-up study of 1201 patients.

Authors:  Peter Vestergaard; Leif Mosekilde
Journal:  World J Surg       Date:  2003-02-27       Impact factor: 3.352

6.  Influence of calcium-sensing receptor gene on urinary calcium excretion in stone-forming patients.

Authors:  Giuseppe Vezzoli; Annalisa Tanini; Luigi Ferrucci; Laura Soldati; Cristiana Bianchin; Francesco Franceschelli; Cecilia Malentacchi; Berardino Porfirio; Donatella Adamo; Annalisa Terranegra; Alberto Falchetti; Daniele Cusi; Giuseppe Bianchi; Maria Luisa Brandi
Journal:  J Am Soc Nephrol       Date:  2002-10       Impact factor: 10.121

7.  Silent renal stones in primary hyperparathyroidism: prevalence and clinical features.

Authors:  Sara Cassibba; Micaela Pellegrino; Laura Gianotti; Claudia Baffoni; Enrico Baralis; Roberto Attanasio; Andrea Guarnieri; Giorgio Borretta; Francesco Tassone
Journal:  Endocr Pract       Date:  2014-11       Impact factor: 3.443

8.  Hospital care for primary hyperparathyroidism in Italy: a 6-year register-based study.

Authors:  Cristiana Cipriani; Vincenzo Carnevale; Federica Biamonte; Sara Piemonte; Jessica Pepe; Luciano Nieddu; John P Bilezikian; Salvatore Minisola
Journal:  Eur J Endocrinol       Date:  2014-07-11       Impact factor: 6.664

9.  Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop.

Authors:  John P Bilezikian; Maria Luisa Brandi; Richard Eastell; Shonni J Silverberg; Robert Udelsman; Claudio Marcocci; John T Potts
Journal:  J Clin Endocrinol Metab       Date:  2014-08-27       Impact factor: 5.958

10.  Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.

Authors:  Shonni J Silverberg; Bart L Clarke; Munro Peacock; Francisco Bandeira; Stephanie Boutroy; Natalie E Cusano; David Dempster; E Michael Lewiecki; Jian-Min Liu; Salvatore Minisola; Lars Rejnmark; Barbara C Silva; Marcella D Walker; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2014-08-27       Impact factor: 5.958

View more
  23 in total

1.  Occult urolithiasis in asymptomatic primary hyperparathyroidism.

Authors:  Yu-Kwang Donovan Tay; Minghao Liu; Leonardo Bandeira; Mariana Bucovsky; James A Lee; Shonni J Silverberg; Marcella D Walker
Journal:  Endocr Res       Date:  2018-02-05       Impact factor: 1.720

2.  Hypercalciuria: its value as a predictive risk factor for nephrolithiasis in asymptomatic primary hyperparathyroidism?

Authors:  F Saponaro; F Cetani; L Mazoni; M Apicella; M Di Giulio; F Carlucci; M Scalese; E Pardi; S Borsari; J P Bilezikian; C Marcocci
Journal:  J Endocrinol Invest       Date:  2019-12-23       Impact factor: 4.256

3.  Urinary Tract Stones and Osteoporosis: Findings From the Women's Health Initiative.

Authors:  Laura D Carbone; Kathleen M Hovey; Christopher A Andrews; Fridtjof Thomas; Mathew D Sorensen; Carolyn J Crandall; Nelson B Watts; Monique Bethel; Karen C Johnson
Journal:  J Bone Miner Res       Date:  2015-07-14       Impact factor: 6.741

Review 4.  Primary Hyperparathyroidism.

Authors:  John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

Review 5.  [Asymptomatic primary hyperparathyroidism : Operation or observation?]

Authors:  Katja Gollisch; Heide Siggelkow
Journal:  Internist (Berl)       Date:  2021-03-12       Impact factor: 0.743

6.  Mild primary hyperparathyroidism as defined in the Italian Society of Endocrinology's Consensus Statement: prevalence and clinical features.

Authors:  E Castellano; F Tassone; R Attanasio; L Gianotti; M Pellegrino; G Borretta
Journal:  J Endocrinol Invest       Date:  2015-11-30       Impact factor: 4.256

7.  Successful treatment of recurrent renal stones with Cinacalcet in a patient with primary hyperparathyroidism.

Authors:  Priyesh Chauhan; Neil J Gittoes; Tarekegn Geberhiwot
Journal:  BMJ Case Rep       Date:  2016-08-12

Review 8.  Primary hyperparathyroidism.

Authors:  John P Bilezikian; Natalie E Cusano; Aliya A Khan; Jian-Min Liu; Claudio Marcocci; Francisco Bandeira
Journal:  Nat Rev Dis Primers       Date:  2016-05-19       Impact factor: 52.329

Review 9.  Primary hyperparathyroidism.

Authors:  Marcella D Walker; Shonni J Silverberg
Journal:  Nat Rev Endocrinol       Date:  2017-09-08       Impact factor: 43.330

10.  Clinical presentation and management of patients with primary hyperparathyroidism in Italy.

Authors:  F Saponaro; F Cetani; A Repaci; U Pagotto; C Cipriani; J Pepe; S Minisola; C Cipri; F Vescini; A Scillitani; A Salcuni; S Palmieri; C Eller-Vainicher; I Chiodini; B Madeo; E Kara; E Castellano; G Borretta; L Gianotti; F Romanelli; V Camozzi; A Faggiano; S Corbetta; L Cianferotti; M L Brandi; M L De Feo; A Palermo; G Vezzoli; F Maino; M Scalese; C Marcocci
Journal:  J Endocrinol Invest       Date:  2018-04-03       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.